当前位置:首页 - 行情中心 - 昭衍新药(603127) - 财务分析 - 现金流量表

昭衍新药

(603127)

  

流通市值:251.89亿  总市值:299.44亿
流通股本:6.30亿   总股本:7.49亿

现金流量表

报告期2026-03-312025-12-312025-09-302025-06-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金548,028,113.11,772,381,774.151,273,147,554.37835,220,095.37
  收到的税费返还975,507.757,291,392.166,368,337.793,521,200.65
  收到其他与经营活动有关的现金7,844,283.1952,454,155.5443,956,095.0337,237,275.84
  经营活动现金流入小计556,847,904.041,832,127,321.851,323,471,987.19875,978,571.86
  购买商品、接受劳务支付的现金181,582,001.45567,303,820.73401,692,918.2255,061,869.13
  支付给职工以及为职工支付的现金207,289,895.12658,177,529.56528,437,549.04362,670,351.19
  支付的各项税费22,622,089.9363,156,061.1752,826,422.9944,636,272.58
  支付其他与经营活动有关的现金17,742,754.4698,923,188.2674,123,947.6450,837,084.13
  经营活动现金流出小计429,236,740.961,387,560,599.721,057,080,837.87713,205,577.03
  经营活动产生的现金流量净额127,611,163.08444,566,722.13266,391,149.32162,772,994.83
二、投资活动产生的现金流量:
  收回投资收到的现金1,415,062,758.672,276,223,325.911,903,795,691.671,017,911,291.67
  取得投资收益收到的现金22,020,747.9575,133,433.2462,042,621.8520,527,967.29
  处置固定资产、无形资产和其他长期资产收回的现金净额13,2501,361,360.161,145,178.4636,965.24
  收到的其他与投资活动有关的现金-17,793,632.08--
  投资活动现金流入小计1,437,096,756.622,370,511,751.391,966,983,491.981,038,476,224.2
  购建固定资产、无形资产和其他长期资产支付的现金369,283,452.94143,602,144.53121,121,329.5689,303,769.24
  投资支付的现金1,110,000,0002,646,102,552.692,110,584,774.911,384,184,774.91
  投资活动现金流出小计1,479,283,452.942,789,704,697.222,231,706,104.471,473,488,544.15
  投资活动产生的现金流量净额-42,186,696.32-419,192,945.83-264,722,612.49-435,012,319.95
三、筹资活动产生的现金流量:
  分配股利、利润或偿付利息支付的现金-22,385,22922,385,229-
  支付其他与筹资活动有关的现金5,447,459.8244,598,826.3136,603,316.9128,180,254.57
  筹资活动现金流出小计5,447,459.8266,984,055.3158,988,545.9128,180,254.57
  筹资活动产生的现金流量净额-5,447,459.82-66,984,055.31-58,988,545.91-28,180,254.57
四、汇率变动对现金及现金等价物的影响-8,746,427.18-11,738,509.02-5,822,610.67-2,551,375.3
五、现金及现金等价物净增加额71,230,579.76-53,348,788.03-63,142,619.75-302,970,954.99
  加:期初现金及现金等价物余额911,854,340.56965,203,128.59965,203,128.59965,203,128.59
  期末现金及现金等价物余额983,084,920.32911,854,340.56902,060,508.84662,232,173.6
补充资料:
  净利润-297,842,526.3-60,932,376.38
  资产减值准备-156,760,636.98-66,010,456.08
  固定资产和投资性房地产折旧-94,903,390.14-45,228,713.36
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-94,903,390.14-45,228,713.36
  无形资产摊销-17,422,245.12-8,041,663.14
  长期待摊费用摊销-19,269,954.04-10,656,937.26
  递延收益摊销-4,818,186.92-8,924,489.34
  处置固定资产、无形资产和其他长期资产的损失--413,517.67-44,025.87
  固定资产报废损失-461,919.3--152,132.42
  公允价值变动损失--447,560,334.54--107,019,073.28
  财务费用--53,994,754.17--30,344,182.68
  投资损失--18,013,906.02--13,135,262.03
  递延所得税-119,241.75-1,267,989.53
  其中:递延所得税资产减少--6,320,664.55-3,917,588.08
    递延所得税负债增加-6,439,906.3--2,649,598.55
  存货的减少-214,517,124.57--24,389,766.63
  经营性应收项目的减少-62,295,986.6-84,804,281.28
  经营性应付项目的增加-68,228,112.06-43,202,349.46
  现金的期末余额-911,854,340.56-662,232,173.6
  减:现金的期初余额-965,203,128.59-965,203,128.59
  现金及现金等价物的净增加额--53,348,788.03--302,970,954.99
公告日期2026-04-302026-03-312025-10-312025-08-27
审计意见(境内)标准无保留意见
TOP↑